Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, December 1, 2022
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
[ Thu, Dec 01st 2022
] - WOPRAI
Douglas Tsao Initiated (VRDN) at Strong Buy and Held Target at $35 on, Dec 1st, 2022
Douglas Tsao of HC Wainwright & Co., Initiated "Viridian Therapeutics, Inc." (VRDN) at Strong Buy and Held Target at $35 on, Dec 1st, 2022.
Douglas has made no other calls on VRDN in the last 4 months.
There are 3 other peers that have a rating on VRDN. Out of the 3 peers that are also analyzing VRDN, 0 agree with Douglas's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Douglas
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $46 on, Tuesday, November 15th, 2022
- Michael Higgins of "Ladenburg Thalmann" Maintained at Strong Buy with Increased Target to $40 on, Tuesday, August 16th, 2022
- Mike Kratky of "SVB Leerink" Maintained at Buy with Increased Target to $40 on, Monday, August 15th, 2022
